Application of DIRECT Target Enrichment to Next-Generation Sequencing of Challenging Clinical Samples

摘要

Next-generation sequencing (NGS) of patient DNA has profoundly impacted the ability to provide targeted therapies for the treatment of a wide variety of diseases. As the use of NGS in the clinic expands, there is an increasing need for sample preparation methods that produce highly sensitive data for variant detection. To be clinically relevant, these methods must be compatible with challenging samples, such as FFPE DNA, which may have extensive DNA damage, or cell-free circulating tumor DNA, which often requires detection of variants present at low proportions.